High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial-Reference-Cited by-同舟云学术

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Published:2017-01 Issue:1 Volume:17 Page:39-49
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Boeree Martin J,Heinrich Norbert,Aarnoutse Rob,Diacon Andreas H,Dawson Rodney,Rehal Sunita,Kibiki Gibson S,Churchyard Gavin,Sanne Ian,Ntinginya Nyanda E,Minja Lilian T,Hunt Robert D,Charalambous Salome,Hanekom Madeleine,Semvua Hadija H,Mpagama Stellah G,Manyama Christina,Mtafya Bariki,Reither Klaus,Wallis Robert S,Venter Amour,Narunsky Kim,Mekota Anka,Henne Sonja,Colbers Angela,van Balen Georgette Plemper,Gillespie Stephen H,Phillips Patrick P J,Hoelscher Michael

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference35 articles.

1. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications;Fox;Int J Tuberc Lung Dis,1999

2. Why do we use 600 mg of rifampicin in tuberculosis treatment?;van Ingen;Clin Infect Dis,2011

3. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model;de Steenwinkel;Am J Respir Crit Care Med,2013

4. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo;Hu;Front Microbiol,2015

5. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis;Rosenthal;Antimicrob Agents Chemother,2012

Cited by 309 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis;Trends in Parasitology;2024-09

2. Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles;The Lancet Microbe;2024-09

3. ISCCM Position Statement on the Approach to and Management of Critically Ill Patients with Tuberculosis;Indian Journal of Critical Care Medicine;2024-08-10

4. Elderly patients with tuberculosis in a low-incidence country – Clinical characteristics, inflammation and outcome;Journal of Infection;2024-08

5. Tryptophan and Its derived Metabolites as Biomarkers for Tuberculosis Disease: A Systematic Review;IRAN BIOMED J;2024